Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care

Clinical Chemistry

Volumn 49, Issue 8, 2003, Pages 1337-1346

  Alehagen, Urban ^a   Lindstedt, Göran ^b   Eriksson, Henry ^c   Dahlström, Ulf ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; UNCLASSIFIED DRUG;

AGED; AGING; ARTICLE; CARDIOMEGALY; CONTROLLED STUDY; DIASTOLE; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; HEALTH CARE UTILIZATION; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LUNG BLOOD FLOW; MAJOR CLINICAL STUDY; MALE; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; PRIMARY HEALTH CARE; PROTEIN DETERMINATION; RADIOIMMUNOASSAY; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; CARDIOMEGALY; DIASTOLE; ECHOCARDIOGRAPHY, DOPPLER; EDEMA; FAMILY PRACTICE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY; MALE; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PROTEIN PRECURSORS; ROC CURVE; SYSTOLE; VENTRICULAR DYSFUNCTION;

EID: 0041866785     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.8.1337     Document Type: Article

References (39)

1. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202.
2. Vasan RS, Levy D, Larson MG, Benjamin EJ. Interpretation of echocardiographic measurements: a call for standardization. Am Heart J 2000;139:412-22.
3. Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci (Lond) 1998; 95:519-29.
4. Clerico A, Iervasi G, Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999;31:487-98.
5. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571-88.
6. Maisel A. B-type natriuretic peptide levels: a potential novel "white count" for congestive heart failure. J Card Fail 2001;7:183-93.
7. Boomsma F, van den Meiracker AH. Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res 2001;51:442-9.
8. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993; 76:91-6.
9. Pemberton CJ, Johnson ML, Yandle TG, Espiner EA. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 2000;36:355-9.
10. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
11. Stein BC, Levin RI. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am Heart J 1998;135:914-23.
12. Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 1995;214:1175-83.
13. Schulz H, Langvik TA, Lund Sagen E, Smith J, Ahmadi N, Halt C. Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma. Scand J Clin Lab Invest 2001;61:33-42.
14. Waku S, Iida N, Ishihara T. Significance of brain natriuretic peptide measurement as a diagnostic indicator of cardiac function. Methods Inf Med 2000;39:249-53.
15. Talwar S, Siebenhofer A, Williams B, Ng L. Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP. Heart 2000;83:278-82.
16. Suzuki M, Yamamoto K, Watanabe S, Iwata T, Hamada M, Hiwada K. Association between elevated brain natriuretic peptide levels and the development of left ventricular hypertrophy in patients with hypertension. Am J Med 2000;108:627-33.
17. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Heid IM, Muders F, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000;18:1121-8.
18. Groenning BA, Nilsson JC, Sondergaard L, Kjaer A, Larsson HB, Hildebrandt PR. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations. Eur J Heart Fail 2001;3:699-708.
19. Davis M, Espiner E, Richards G, Billings J, Town I, Neill A, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994;343:440-4.
20. Alehagen U, Eriksson H, Nylander E, Dahlström U. Heart failure in the elderly. Characteristics of a Swedish primary health care population. Heart Drug 2002;2:211-20.
21. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991;12:315-21.
22. Jensen-Urstad K, Bouvier F, Hojer J, Ruiz H, Hulting J, Samad B, et al. Comparison of different echocardiographic methods with radio-nuclide imaging for measuring left ventricular ejection fraction during acute myocardial infarction treated by thromboiytic therapy. Am J Cardiol 1998;81:538-44.
23. van Royen N, Jaffe CC, Krumholz HM, Johnson KM, Lynch PJ, Natale D, et al. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol 1996;77:843-50.
24. Hanley JA. Receiver operating characteristic (ROC) methodology: the state of the art. Crit Rev Diagn Imaging 1989;29:307-35.
25. Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W, et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 1999;230:177-81.
26. Wallen T, Landahl S, Hedner T, Saito Y, Masuda I, Nakao K. Brain natriuretic peptide in an elderly population. J Intern Med 1997;242:307-11.
27. Goetze JP, Kastrup J, Pedersen F, Rehfeld JF. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin Chem 2002;48:1035-42.
28. Sayama H, Nakamura Y, Saito N, Kinoshita M. Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? Coron Artery Dis 1999;10:537-40.
29. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000;102:203-10.
30. Bando M, Ishii Y, Sugiyama Y, Kitamura S. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med 1999;93:507-14.
31. de Simone G, Verdecchia P, Pede S, Gorini M, Maggioni AP. Prognosis of inappropriate left ventricular mass in hypertension: the MAVI Study. Hypertension 2002;40:470-6.
32. Pemberton CJ, Yandle TG, Rademaker MT, Charles CJ, Aitken GD, Espiner EA. Amino-terminal proBNP in ovine plasma: evidence for enhanced secretion in response to cardiac overload. Am J Physiol 1998;275:H1200-8.
33. Omland T, Aakvaag A, Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment. Heart 1996;76:232-7.
34. Bettencourt P, Ferreira A, Sousa T, Ribeiro L, Brandao F, Polonia J, et al. Brain natriuretic peptide as a marker of cardiac involvement in hypertension. Int J Cardiol 1999;69:169-77.
35. Kawano H, Do YS, Kawano Y, Starnes V, Barr M, Law RE, et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000;101:1130-7.
36. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000;97:4239-44.
37. Ogawa Y, Tamura N, Chusho H, Nakao K. Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. Can J Physiol Pharmacol 2001;79:723-9.
38. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, et al. Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002;91:1127-34.
39. Chen HH, Lainchbury JG, Harty GJ, Burnett JC Jr. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation 2002;105:999-1003.